In The News
Featured Evidence
- June 20, 2023
New Diabetes Technology and Therapeutics Supplement Highlights the Latest CGM Evidence and Insights
Learn MorePrescribing of CGM in clinical practice and payer coverage criteria have expanded considering the wealth of evidence and expert recommendations supporting more widespread use. As the body of evidence continues to grow, a new supplement in Diabetes Technology & Therapeutics offers insights from leading clinicians on the latest findings and practical application of CGM. The...
- November 11, 2022
WISDM Trial: Hypoglycemia Avoidance Associated with rtCGM Sustained Out to 12 Months in Older Adults
Learn More
- June 21, 2021
Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial
Learn More

Latest Expert Interview
Addressing Disparities in Care with Evidence-Based Utilization of Diabetes Technology
Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute
Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM
Watch Now View All InterviewsValue of CGM
more patients using rtCGM achieve HEDIS-compliant HbA1C<8% compared with BGM
1
1. Karter AJ, et al. JAMA. 2021;325:2273-2284. doi: 10.1001/jama.2021.6530.
Click here to access
of patients report modifying lifestyle choices due to rtCGM feedback
2
2. Ehrhardt N, et al. Clin Diabetes. 2020;38:126-131. doi: 10.2337/cd19-0037.
Click here to access
in PMPM savings in T2 diabetes related costs according to claims analyses of rtCGM users
3, 4
3. Norman GJ, et al. Diabetes Technol Ther.
2022;24:520-524. doi: 10.1089/dia.2021.0525.
Click here to access
4. Isaacson B, et al. J Diabetes Sci Technol.
2022;16:383-389. doi: 10.1177/1932296820955228.
Click here to access